Paradigm Biopharmaceuticals Limited (PBIGF)
USD 0.14
(0.0%)
USD 0.14
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 3.58 Million AUD | -73.23% |
| 2023 | 13.39 Million AUD | 59.88% |
| 2022 | 8.37 Million AUD | 28.49% |
| 2021 | 6.51 Million AUD | 55.88% |
| 2020 | 4.18 Million AUD | 54.62% |
| 2019 | 2.7 Million AUD | 103.8% |
| 2018 | 1.32 Million AUD | 38.92% |
| 2017 | 955.28 Thousand AUD | -14.45% |
| 2016 | 1.11 Million AUD | 93.42% |
| 2015 | 577.32 Thousand AUD | 56.6% |
| 2014 | 368.66 Thousand AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 3.58 Million AUD | -68.11% |
| 2024 Q4 | 3.58 Million AUD | 0.0% |
| 2024 Q1 | 11.23 Million AUD | -16.07% |
| 2024 Q2 | 11.23 Million AUD | 0.0% |
| 2024 FY | 3.58 Million AUD | -73.23% |
| 2023 Q3 | 13.39 Million AUD | -9.75% |
| 2023 Q4 | 13.39 Million AUD | 0.0% |
| 2023 Q1 | 14.83 Million AUD | 77.16% |
| 2023 Q2 | 14.83 Million AUD | 0.0% |
| 2023 FY | 13.39 Million AUD | 59.88% |
| 2022 Q1 | 14.57 Million AUD | 123.58% |
| 2022 FY | 8.37 Million AUD | 28.49% |
| 2022 Q4 | 8.37 Million AUD | 0.0% |
| 2022 Q3 | 8.37 Million AUD | -42.53% |
| 2022 Q2 | 14.57 Million AUD | 0.0% |
| 2021 FY | 6.51 Million AUD | 55.88% |
| 2021 Q1 | 5.83 Million AUD | 39.46% |
| 2021 Q2 | 5.83 Million AUD | 0.0% |
| 2021 Q3 | 6.51 Million AUD | 11.78% |
| 2021 Q4 | 6.51 Million AUD | 0.0% |
| 2020 Q4 | 4.18 Million AUD | 0.0% |
| 2020 FY | 4.18 Million AUD | 54.62% |
| 2020 Q1 | 1.97 Million AUD | -27.05% |
| 2020 Q2 | 1.97 Million AUD | 0.0% |
| 2020 Q3 | 4.18 Million AUD | 111.97% |
| 2019 Q2 | 1.15 Million AUD | 0.0% |
| 2019 Q3 | 2.7 Million AUD | 134.88% |
| 2019 Q4 | 2.7 Million AUD | 0.0% |
| 2019 FY | 2.7 Million AUD | 103.8% |
| 2019 Q1 | 1.15 Million AUD | -13.23% |
| 2018 Q1 | 1.36 Million AUD | 42.57% |
| 2018 Q2 | 1.36 Million AUD | 0.0% |
| 2018 Q3 | 1.32 Million AUD | -2.56% |
| 2018 FY | 1.32 Million AUD | 38.92% |
| 2018 Q4 | 1.32 Million AUD | 0.0% |
| 2017 Q1 | 1.63 Million AUD | 46.21% |
| 2017 FY | 955.28 Thousand AUD | -14.45% |
| 2017 Q4 | 955.28 Thousand AUD | 0.0% |
| 2017 Q3 | 955.28 Thousand AUD | -41.49% |
| 2017 Q2 | 1.63 Million AUD | 0.0% |
| 2016 Q1 | 420.25 Thousand AUD | -28.2% |
| 2016 Q3 | 1.11 Million AUD | 165.72% |
| 2016 Q4 | 1.11 Million AUD | 0.0% |
| 2016 Q2 | 420.25 Thousand AUD | 0.0% |
| 2016 FY | 1.11 Million AUD | 93.42% |
| 2015 FY | 577.32 Thousand AUD | 56.6% |
| 2015 Q1 | - AUD | 0.0% |
| 2015 Q4 | 585.28 Thousand AUD | 0.0% |
| 2014 FY | 368.66 Thousand AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 6.357% |
| CSL Limited | 18.62 Billion USD | 99.981% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 93.276% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 62.593% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -750.24% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 95.054% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 93.926% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 6.935% |
| Mesoblast Limited | 188.44 Million USD | 98.098% |
| Marizyme, Inc. | 26.67 Million USD | 86.563% |
| Genus plc | 485 Million USD | 99.261% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 38.652% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -42.443% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 5.675% |
| ContraFect Corporation | 32.53 Million USD | 88.982% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -80.908% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| IMV Inc. | 37.93 Million USD | 90.551% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 69.568% |
| MultiCell Technologies, Inc. | 1617.67 USD | -221474.301% |
| Accustem Sciences Inc. | 1.07 Million USD | -232.117% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 95.37% |
| EV Biologics, Inc. | 2.11 Million USD | -69.467% |
| Q BioMed Inc. | 8.13 Million USD | 55.928% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 95.678% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 30.348% |
| Biomind Labs Inc. | 1.49 Million USD | -139.177% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 80.524% |
| Skye Bioscience, Inc. | 14.07 Million USD | 74.529% |
| SQZ Biotechnologies Company | 50.03 Million USD | 92.837% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -2422.496% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 62.134% |
| Intellipharmaceutics International Inc. | 12 Million USD | 70.152% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -1682.226% |
| Neon Bloom, Inc. | 1.22 Million USD | -192.31% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 98.531% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -78.314% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 37.618% |
| GB Sciences, Inc. | 5.41 Million USD | 33.838% |
| Alpha Cognition Inc. | 7.16 Million USD | 49.973% |
| argenx SE | 444.95 Million USD | 99.194% |
| HST Global, Inc. | 593.59 Thousand USD | -503.838% |
| Halberd Corporation | 728.71 Thousand USD | -391.869% |
| Enzolytics Inc. | 365.26 Million USD | 99.019% |
| Resverlogix Corp. | 67.39 Million USD | 94.682% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -327.352% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 95.216% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 96.981% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -109.121% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 60.36% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 85.515% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -149.978% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 69.887% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 2.205% |
| AVAX Technologies, Inc. | 3.99 Million USD | 10.251% |
| ONE Bio Corp. | 27.49 Million USD | 86.964% |
| Zenith Capital Corp. | 27.56 Thousand USD | -12901.346% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.73% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -1401.899% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 4.016% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -426.463% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -32.183% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -184.654% |
| Agentix Corp. | 2.51 Million USD | -42.771% |
| Adynxx, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 3.5 Million USD | -2.268% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -5255.438% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 92.869% |
| BioStem Technologies, Inc. | 15.9 Million USD | 77.464% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -671.325% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -12965.8% |
| LadRx Corporation | 2.2 Million USD | -62.885% |
| Cell Source, Inc. | 15.8 Million USD | 77.324% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -7919.378% |
| Regen BioPharma, Inc. | 5.45 Million USD | 34.324% |
| Regen BioPharma, Inc. | 5.45 Million USD | 34.324% |
| NovAccess Global Inc. | 7.86 Million USD | 54.402% |
| Affymax, Inc. | 8.87 Million USD | 59.595% |
| Itoco Inc. | 1.65 Million USD | -116.819% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -74.713% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 40.745% |
| CytoDyn Inc. | 127.89 Million USD | 97.197% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -8475.184% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -128.83% |
| Qrons Inc. | 1.48 Million USD | -140.768% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 67.549% |
| SYBLEU INC | 681.41 Thousand USD | -426.016% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -343.171% |
| Rebus Holdings, Inc. | 5.24 Million USD | 31.623% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 41.259% |
| Mobile Lads Corp. | 1.31 Million USD | -172.885% |
| International Stem Cell Corporation | 5.27 Million USD | 32.076% |
| Bioxytran, Inc. | 3.24 Million USD | -10.304% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -472.753% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 22.369% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 91.257% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 83.901% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -76.971% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 34.568% |
| Neutra Corp. | 973.52 Thousand USD | -268.18% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 87.647% |
| PureTech Health plc | 125.58 Million USD | 97.146% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 4.599% |
| IXICO plc | 1.9 Million USD | -88.621% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 82.54% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 96.531% |
| CSL Limited | 18.62 Billion USD | 99.981% |
| Cellectis S.A. | 249.36 Million USD | 98.563% |